Stock Events

Stock Events

Lidds AB 

SEK0.02
2
+SEK0+11.82% Friday 10:00

Statistics

Day High
0.02
Day Low
0.02
52W High
0.2
52W Low
0.01
Volume
15,794
Avg. Volume
204,747
Mkt Cap
3.36M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

15MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.23
0.1
0.43
0.77
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-11.88MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LIDDS.ST. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap276.38B
Merck & Co., Inc. develops similar oncology drugs and therapies, competing in the pharmaceuticals market.
Pfizer
PFE
Mkt Cap153.59B
Pfizer Inc. is a major player in the development and manufacturing of drugs, including cancer treatments that compete with Lidds AB's offerings.
Novartis
NVS
Mkt Cap280.79B
Novartis AG focuses on innovative medicines including oncology, directly competing with Lidds AB's cancer treatment technologies.
Bristol-Myers Squibb
BMY
Mkt Cap119.87B
Bristol-Myers Squibb Company specializes in biopharmaceuticals, including cancer drugs that rival Lidds AB's products.
Lilly(Eli) &
LLY
Mkt Cap789.69B
Eli Lilly and Company produces pharmaceutical products, including cancer therapies that compete in the same market as Lidds AB.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca PLC engages in the development of various therapeutic areas, including oncology, competing with Lidds AB's cancer-focused treatments.
Roche
RHHBY
Mkt Cap332.61B
Roche Holding AG is a major healthcare company that develops cancer treatments, which are in direct competition with Lidds AB's products.
AMGEN
AMGN
Mkt Cap185.74B
Amgen Inc. focuses on human therapeutics, including oncology, which competes with Lidds AB's cancer treatment solutions.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences, Inc. develops and markets drugs for life-threatening diseases including cancer, competing with Lidds AB.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals, Inc. is involved in biopharmaceutical development, including oncology drugs that compete with Lidds AB's portfolio.

About

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden.
Show more...
CEO
Mats Wiking
Employees
1
Country
Sweden
ISIN
SE0001958612

Listings

0 Comments

Share your thoughts

FAQ

What is Lidds AB stock price today?▼
The current price of LIDDS.ST is SEK0.02 SEK — it has increased by +11.82% in the past 24 hours. Watch Lidds AB stock price performance more closely on the chart.
What is Lidds AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lidds AB stocks are traded under the ticker LIDDS.ST.
Is Lidds AB stock price growing?▼
LIDDS.ST stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Lidds AB has showed a -47.44% decrease.
What is Lidds AB market cap?▼
Today Lidds AB has the market capitalization of 3.36M
What is Lidds AB revenue for the last year?▼
Lidds AB revenue for the last year amounts to 0 SEK.
What is Lidds AB net income for the last year?▼
LIDDS.ST net income for the last year is -11.88M SEK.
How many employees does Lidds AB have?▼
As of April 29, 2026, the company has 1 employees.
In which sector is Lidds AB located?▼
Lidds AB operates in the Health & Wellness sector.
When did Lidds AB complete a stock split?▼
Lidds AB has not had any recent stock splits.
Where is Lidds AB headquartered?▼
Lidds AB is headquartered in Stockholm, Sweden.